OncoMed Says CMO Dupont Has Resigned And Expects Return To Genentech/Roche

OncoMed Pharmaceuticals Inc. said early Monday that Chief Medical Officer Jakob Dupont had resigned, effective early 2017, and that he plans a return to Genentech/Roche . The company said it has started a search for its next CMO. Dupont's resignation was due to "personal and family-related issues," OncoMed said. Dupont worked at Roche, and before that Genentech, for about five years, according to his LinkedIn profile, and his return to the company should be "a position of significant responsibility in oncology clinical development," OncoMed said. OncoMed shares, which were not active in pre-market trade, dropped 62.4% year-to-date to $8.48 per share, compared with a 7.2% rise in the S&P 500 .